Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP568 | DOI: 10.1530/endoabs.49.EP568

ECE2017 Eposter Presentations: Diabetes, Obesity and Metabolism Diabetes complications (102 abstracts)

Tubular and glomerular biomarkers of kidney injury on glucagon-like peptide-1 (GLP-1) therapy in type 1 diabetic patients

Zamira Zuraeva 2 , Olga Vikulova 1, , Olga Mikhaleva 2 , Marina Shestakova 1, , Aleksandr Ilyin 1 , Minara Shamkhalova 1, & Ivan Dedov 1


1Endocrinology Research Center, Moscow, Russia; 2I.M. Sechenov First Moscow State Medical University, Moscow, Russia.

Background and aims: To evaluate the level of tubular and glomerular biomarkers of kidney injury as potential nephroprorotective effects of GLP-1R agonist (liraglutide) addition in type 1 diabetic patients compared to standard insulin therapy.

Materials and methods: 12 T1DM patients with normo-(AER <20 mg/l, n=7) and microalbuminuria (AER<199 mg/l, n=5) with liraglutide 1.2 mg as add on to insulin for 6 month and 12 patients with normo-(AER <20 mg/l, n=8) and microalbuminuria(AER<199 mg/l, n=4) on standard insulin therapy. Biomarkers of kidney damage (collagen i.v., nephrin, podocin, cystatin C, kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), uromodulin, osteopontin) were measured by enzyme-linked immunosorbent assay ELISA in the morning urine and fasting plasma; overnight AER by immunoturbidimetry assay; glomerular filtration rate (GFR) by CKD-EPI formula were measured before and after 6-month treatment. Concomitant RAAS blockage-drugs given in stable doses. Differences were examined for statistical significanse (P<0.05) using Wilcoxon Signed-Rank Test.

Results: Initially the groups were similar by average age, HbA1c, plazma glucose, BP, lipids, uric acid, C-reactive protein, creatinine, eGFR. HbA1c before and after 6 month treatment. There were no significant differences in BP, albuminuria, creatinine, eGFR, HbA1c in 6 month. BMI decreased from 29 (22;38) to 26.8 (21;34.7) kg/m2, P=0.01 in GLP1 group. Urinary levels of podocin, KIM-1 and collagen did not changed before and after therapy. In GLP1 group observed significant reduction in the urinary levels of NGAL/creatinine 1.48(0.81;2.29) vs 0.65(0.34;0.74) ng/mmol, P=0.015; KIM-1/creatinine 115(35;328) vs 47(21;116) ng/mmol, P=0.02; cystatin C 881(464;1579) vs 136(91;205) ng/mmol, P=0.01; nephrin 0.1(0.09;0.15) vs 0.004(0.01;0.1), uromodulicreatinine rised from 175(82;278) to 458 (235;754); and plazma levels of cystatin and osteopontin after treatment: 1264 (877;1472) vs 722 (672;848) ng/ml, P=0.007; 126.8 (45;161) vs 65 (45;74), P=0.02, respectively compared to the stable levels of markers in the standard insulin treatment group.

Conclusion: The present data suggest that GLP-1R adding to standard insulin therapy might be effective for the weight reduction and as potential nephroprotective strategy for attenuating the chronic kidney injury in T1DM.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.